

**Vivimed**

Date: 14.02.2025

To

BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001  
**BSE - Code : 532660**

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
**NSE- Symbol: VIVIMEDLAB**

Dear Sir/Madam,

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.**

The Board of Directors of the Company at its meeting held on February 14, 2025 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter and nine months ended December 31, 2024 attached herewith;
2. Auditors's Limited Review Report on the Un-audited Financial Results of the Company for the Quarter and nine months ended December 31, 2024.


The Board meeting concluded at 21.10 Hrs.

You are requested to take note of the above.

Yours faithfully

**For VIVIMED LABS LIMITED**

**SANTOSH VARALWAR  
MANAGING DIRECTOR**



Vivimed Labs Limited.  
CIN:L02411KA1968PLC009465  
Registered Office: #78/A, Kolhar Industrial Area,  
Bidar, Karnataka - 585 403, India.  
T +91 (0) 8462-232045. F +91 (0) 8462-232436  
Email: [info@vivimedlabs.com](mailto:info@vivimedlabs.com) | [www.vivimedlabs.com](http://www.vivimedlabs.com)

Corporate Office:  
6-3-866/1/G1, 3<sup>rd</sup> Floor, GMR Towers,  
Greenlands, Begumpet, Hyderabad,  
Telangana – 500 016, India.  
GSTIN: 36AAACV6060A 1ZQ  
T +91(0) 40-6608-6608. F +91(0) 40-6608-6699

**VIVIMED LABS LIMITED**  
**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2024**

Rs in Million

Sl. No.	Particulars	3 Months Ended			9M FY 25	9M FY 24	Year Ended 31.03.2024
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	Income From Operations						
1	Revenue from operations	365.10	247.72	414.62	906.55	1,104.55	1,490.71
	Total revenue from operations	365.10	247.72	414.62	906.55	1,104.55	1,490.71
2	Other Income	0.67	0.27	0.39	1.54	25.51	99.76
3	Total Revenue (1+2)	365.77	247.99	415.01	908.09	1,128.06	1,590.47
4	Expenses						
a	Cost of material consumed	147.14	154.71	214.59	500.02	570.64	895.45
b	Changes in inventories of finished goods work in progress and stock-in-Trade	49.73	(41.05)	3.05	-15.94	5.26	(180.71)
c	Employee Benefit Expenses	72.94	62.85	97.54	196.07	271.64	341.55
d	Finance Costs	4.83	4.27	132.11	12.07	357.66	24.32
e	Depreciation and Amortisation Expenses	66.15	41.00	47.04	147.24	141.06	199.41
f	Other Expenses	84.73	77.62	86.71	332.24	306.56	710.39
	Total Expenses	425.52	299.40	581.04	1,171.70	1,652.82	1,990.41
5	Profit before tax (3-4)	(59.75)	(51.41)	(166.03)	(263.61)	(524.76)	(399.94)
6	Prior Period Expenses						
7	Tax expenses						
	Current Taxes	-	-	-	-	-	58.29
	Deferred Taxes	-	-	(5.54)	-	(17.68)	0.18
	Total tax expenses	-	-	(5.54)	-	(17.68)	(3.77)
7	Profit for the period /Year before non-controlling interest (5-6)	(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(454.46)
8	Non-controlling interest						
9	Profit for the period/year (7-8)	(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(454.46)
10	Other comprehensive income						
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	-	5.63
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	5.63
11	Non-controlling interest						
12	Other comprehensive income attributable to shareholders(10+11)						5.63
	Total comprehensive income attributable to:						
	Shareholders of the Company	(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(448.83)
	Non-controlling interest	-	-	-	-	-	-
	Total Comprehensive income	(59.75)	(51.41)	(160.49)	(263.61)	(507.08)	(448.83)
13	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83	165.83
14	Other equity						
15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)						
	(a) Basic	(0.72)	(0.62)	(1.94)	(3.18)	(6.12)	(5.48)
	(b) Diluted	(0.70)	(0.60)	(1.88)	(3.09)	(5.94)	(5.32)


**NOTES:**

- The above consolidated financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 14, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and expressed a modified conclusion thereon.
- These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- In line with provisions of IND-AS 108 Operating segments, the Group has primarily in Pharma Segment and accordingly the segment reporting is not applicable to the company.
- The subsidiaries (100%) considered for the consolidated financial statements for the Quarter and nine months ended December 31, 2024 are Finiso Pharma Private Limited, Vivimed Labs USA Inc, Vivimed Holdings Ltd and Vivimed Labs Mauritius Ltd
- The Company has defaulted in repayment of dues to banks and Financial Institution amounting to Rs 3,746.40 million as on 31.12.2024 as per books of account. All the loan accounts outstanding as on 31.12.2024 are classified as non-performing by the banks. In view of ongoing negotiation with lenders for settlement, interest for the period is not accounted.
- Deferred tax will be calculated at the end of year.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad  
 Date : 14.02.2025

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR



VIVIMED LABS LIMITED


UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2024

Rs. In Million

Sl. No.	Particulars	3 Months Ended			9M FY 24	9M FY 23	Year Ended 31.03.2024
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	<b>Income From Operations</b>						
1	Revenue from Operations	342.33	221.60	371.35	810.29	1,004.11	1,367.97
	<b>Total revenue from operations</b>	<b>342.33</b>	<b>221.60</b>	<b>371.35</b>	<b>810.29</b>	<b>1,004.11</b>	<b>1,367.97</b>
2	Other Income	0.03	0.27	0.37	0.33	22.03	95.72
3	<b>Total Revenue (1+2)</b>	<b>342.36</b>	<b>221.87</b>	<b>371.73</b>	<b>810.62</b>	<b>1,026.15</b>	<b>1,463.70</b>
4	<b>Expenses</b>						
a	Cost of material consumed	158.11	150.22	197.64	477.87	544.69	853.87
b	Changes in inventories of finished goods work in progress and stock-in-Trade	56.06	(41.05)	3.05	(9.61)	5.26	(180.70)
c	Employee Benefit Expenses	59.26	50.91	85.93	159.69	237.57	294.48
d	Finance Costs	4.31	3.73	131.57	10.55	355.95	19.04
e	Depreciation and Amortisation Expenses	63.67	38.62	44.85	140.19	134.55	184.10
f	Other Expenses	70.69	69.37	75.90	302.72	264.75	678.43
	<b>Total Expenses</b>	<b>412.10</b>	<b>271.80</b>	<b>538.94</b>	<b>1,081.41</b>	<b>1,542.77</b>	<b>1,849.22</b>
5	<b>Profit before tax (3-4)</b>	<b>(69.74)</b>	<b>(49.93)</b>	<b>(167.22)</b>	<b>(270.79)</b>	<b>(516.63)</b>	<b>(385.52)</b>
6	<b>Tax Expenses</b>						
	Current Taxes	-	-	-	-	-	58.29
	Deferred Taxes	-	-	(5.54)	-	(17.68)	-
	<b>Total tax expenses</b>	<b>-</b>	<b>-</b>	<b>(5.54)</b>	<b>-</b>	<b>(17.68)</b>	<b>-</b>
7	<b>Profit for the period/Year (5-6)</b>	<b>(69.74)</b>	<b>(49.93)</b>	<b>(161.68)</b>	<b>(270.79)</b>	<b>(498.95)</b>	<b>(443.81)</b>
8	<b>Other Comprehensive income</b>						
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	-	4.76
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4.76</b>
9	<b>Total comprehensive income (7+8)</b>	<b>(69.74)</b>	<b>(49.93)</b>	<b>(161.68)</b>	<b>(270.79)</b>	<b>(498.95)</b>	<b>(439.05)</b>
10	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83	165.83
11	Other equity						
12	<b>Earnings per Share (before Extraordinary Items) (of Rs2/- each)</b>						
	(a) Basic	(0.84)	(0.60)	(1.95)	(3.27)	(6.02)	(5.35)
	(b) Diluted	(0.82)	(0.58)	(1.89)	(3.17)	(5.84)	(5.20)

NOTES:

- The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 14, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed a modified conclusion thereon.
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- In line with provisions of IND-AS 108 Operating segments, the Company has primarily in Pharma Segment and accordingly the segment reporting is not applicable to the company.
- The Company has defaulted in repayment of dues to banks and Financial Institution amounting to Rs 3,746.40 million as on 31.12.2024 as per books of account. All the loan accounts outstanding as on 31.12.2024 are classified as NPA by the banks. In view of ongoing negotiation with lenders for settlement, interest for the period is not accounted.
- Deferred tax will be calculated at the end of year.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR

Place: Hyderabad  
Date: 14.02.2025

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Vivimed Labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**

The Board of Directors  
Vivimed Labs Limited

1. We have reviewed the accompanying "Statement of Unaudited Consolidated Financial Results (the "Statement") of Vivimed Labs Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associates attached herewith for the quarter ended and nine months ended December 31, 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified u/s 143(10) of The Companies act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by SEBI under regulation 33(8) of the Listing Regulations, to the extent applicable.


4. The Statement includes the results of the following entities:

**Holding Company**

Vivimed Labs Limited

**Subsidiaries**

1. Finoso Pharma Private Limited
2. Vivimed Holdings Limited
3. Vivimed Labs USA INC.
4. Vivimed Labs Mauritius Limited



## Associates

### 1. Yantra Green Power Private Limited

#### 5. Basis for Qualified Conclusion

Based on information provided to us by management, Holding Company has not provided for interest expenses of ₹ 88.18 million on an accrual basis for the Quarter ended 31.12.2024 (₹256.22 million for the year to date 31.12.2024), pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards.

#### 6. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph,, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### 7. Other Matters:

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of subsidiaries, whose interim financial results and other financial information reflect total revenues of ₹ 53.42 million for the quarter ended 31-12-2024 (₹ 127.48 million for the year to date 31.12.2024), and total net profit ₹ 9.46 million for the quarter ended 31-12-2024 (₹ 6.63 million for the year to date 31.12.2024), as considered in the "Statement" whose interim financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on "the Statement", in so far as it relates to the affairs of subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

Also, we have not audited or reviewed the comparative financial information appearing in the statement of the corresponding quarter ended 31<sup>st</sup> December 2023. The comparative financial information appearing in the statement of the corresponding quarter ended 31<sup>st</sup> December 2023 are audited by the previous auditor whose report dated 14.02.2024, expressed a modified opinion on those Consolidated financial results.

Our Conclusion is not modified in respect of this matter.

Place: Hyderabad

Date: 14-02-2025

UDIN: 25213487BMMMJO8419

For SVRL & Co.


Chartered Accountants

Firm's Regn No: 016182S

G Ramakrishna

Partner


M. No. 213487



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Review report to  
THE BOARD OF DIRECTORS  
M/S VIVIMED LABS LIMITED

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **VIVIMED LABS LIMITED** ("the Company"), for the Quarter and nine months ended December 31, 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time ("the Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified u/s 143(10) of The Companies act, 2013 and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. **Basis for Qualified Conclusion**  
Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of ₹ 88.18 million on an accrual basis for the Quarter ended 31.12.2024 (₹ 256.22 million for year to date 31.12.2024), pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards
5. **Qualified Conclusion**  
Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying



statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid 'Ind AS 34' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.


**Other Matters:**

We have not audited or reviewed the comparative financial information appearing in the statement of the corresponding quarter ended 31<sup>st</sup> December 2023. The comparative financial information appearing in the statement of the corresponding quarter ended 31<sup>st</sup> December 2023 are audited by the previous auditor whose report dated 14.02.2024, expressed a modified opinion on those Standalone financial statements.

Our Conclusion is not modified in respect of this matter.

**Place: Hyderabad**  
**Date: 14-02-2025**  
**UDIN: 25213487BMMMJN8524**

**For SVRL & Co.**  
**Chartered Accountants**  
**Firm's Regn No: 016182S**



**G Ramakrishna**  
**Partner**  
**M. No. 213487**